Plaque-Derived FFRCT – the only FFRCT with Plaque Concordance – Planned for FDA Submission in Q4-25

PlaqueIQ™, based on CT Virtual Histology™

Enabling patient-specific treatment pathways with PlaqueIQ.

PlaqueIQ is trained and validated on ground-truth histology, the gold standard for plaque characterization.

Plaque detection is just the beginning.

The only CTA-based plaque assessment powered by ground-truth histology

Developed in partnership with world-renowned cardiovascular pathologists, ground truth histology serves as the basis for training Elucid’s powerful algorithm to objectively quantify vessel structure and plaque composition.

Clinical Problem

About half of Americans between ages 45 and 84 have atherosclerosis and don’t know it.¹​

Despite advances in therapeutics, CVD remains the most common cause of death in the world. Moreover, WHO estimates 80 to 90% of heart attacks as preventable. We believe that current diagnostics miss key information on the type of plaque patients have in their arteries. ​

While physicians look at many risk factors to evaluate patient risk, such as age, diet, and lifestyle, the strongest predictor of future events is the amount and type of plaque patients have in their arteries.²​

The Myocardial Infarction Paradox: Patients deemed “low risk” still account for nearly half of all heart attacks.​
A man and woman hiking

1. Hafiane, A. Vulnerable plaque, characteristics, detection, and potential therapies, J. Cardiovasc. Dev. Dis. 6 (3) (2019). Available from: https://www.mdpi.com/2308-3425/6/3/26. ​

2. Pahwa R, Jialal I. Atherosclerosis. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507799/ (accessed 03.17.2023)​

​

Providing physicians with comprehensive patient, vessel, and lesion-level plaque composition and quantification data.

Solution

PlaqueIQ™ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques.​

​Our plaque analysis software offers the potential to provide greater insights into plaque composition when compared to traditional Hounsfield Unit thresholding. PlaqueIQ can provide physicians with the ability to better determine medical management and help visualize and plan their interventional decisions.​

​Our plaque analysis with an actionable report includes 3D visualization of vessel structure, critical arterial volumes, and plaque quantification including lipid rich necrotic core, calcified, and non-calcified components.​

​Elucid, via PlaqueIQ and FFRCT (under development), offers physicians CT Virtual Histology™, where physicians can understand the plaque tissue histology of a patient with a non-invasive test.

Histology Validation

 

Elucid PlaqueIQ algorithms were validated on histopathologic specimens, including calculations of anatomic structure and calculations of tissue characteristics. The histopathologic validation demonstrated the following performance:

Histopathology Values (mm²)

Elucid PlaqueIQ Results Pearson
Correlation Coefficient [95% CI]
Calcified Plaque Area
0-22.73 mm²		 0.95
[0.91, 0.97]
Lipid Rich Necrotic Core (LRNC) Area*
0-56.36mm²		 0.88
[0.80, 0.93]
Non-Calcified Matrix Area
7.43-55.91 mm²		 0.86
[0.76, 0.92]

*LRNC Area includes areas of LRNC and Intra-Plaque Hemorrhage as identified by pathologists

Elucid PlaqueIQ™

  • Tailor treatment to patient-specific vasculature
  • Utilize actionable, risk-based, lesion-specific plaque composition
  • Support clinical decisions such as intervention versus drug-therapy
  • Supports physician understanding of patient risk to tailor medical guidance and prevent heart attack and stroke
  • Visualize the plaque type and amount in a patient’s vessels, to support physician assessment of stable plaque versus more high-risk plaque
  • Supports physician determination of the most appropriate therapy based on the patient’s unique plaque composition
  • If you are interested in submitting a proposal for a research study, please click here
PlaqueIQ™ Technology

PlaqueIQ Results are Delivered to Physicians in Two Ways

Visualize lesion-level plaque composition, including Calcified Plaque, Non-Calcified Matrix, and Lipid Rich Necrotic Core

1
A DICOM-wrapped PDF delivered to PACS
2
A link to an interactive browser that allows a physician to interrogate the coronary tree and Elucid segmentation in greater detail

The Elucid algorithms demonstrate excellent correlation and are highly accurate for tissue characterization when compared to ex vivo histopathology.”

Renu Virmani, MD

President & Medical Director at CVPath Institute

Secure, Workflow-Oriented Technology

News

Elucid to Showcase PlaqueIQ at SCCT 2025

Jul 10, 2025 |

Opportunity to demo the only FDA-cleared, non-invasive plaque analysis based on objective ground truth histology, the gold standard for characterization of plaques BOSTON – July 10, 2025 – Elucid, an AI medical technology company focused on providing physicians with a...

read more
More News
About

Plaque detection is just the beginning.

PlaqueIQ™ is trained and validated on ground-truth histology, the gold standard for plaque characterization, providing physicians with comprehensive patient, vessel, and lesion-level plaque composition and quantification data.

Our Portfolio

Elucid PlaqueIQ™

The only FDA-cleared, non-invasive CTA plaque assessment that’s powered by ground-truth histology.

Elucid FFRCT

Leveraging histology-based plaque composition to calculate lesion-level FFRCT measurements. Coming soon!

Elucid Clinical Research

Use Elucid’s CTA analysis capabilities for potential research on events tracking, pharma research and more.

Elucid Leadership
Scott Huennekens

Scott Huennekens

Chairman of the Board

Kelly Huang, PhD

Kelly Huang, PhD

President & CEO

Blake Richards

Blake Richards

Chief Operating Officer

Andrew Miller

Andrew Miller

Chief Technology Officer & SVP, Engineering

Windi Hary

Windi Hary

Chief Regulatory & Quality Officer

Sophie Khem

Sophie Khem

SVP, Clinical Quality & Delivery

Amy Kruglak

Amy Kruglak

SVP, People & Leadership Development

Kevin Mathews

Kevin Mathews

SVP, Marketing

Amir Ahmadi, MD

Amir Ahmadi, MD

Lead Scientific Advisor

Contact

Contact us today to learn more about Elucid or to schedule a product demo.

Name
By providing a telephone number and submitting this form you are consenting to be contacted by SMS text message. Message & data rates may apply. You can reply STOP to opt-out of further messaging.

info@elucid.com

399 Boylston Street, Suite 400
Boston, MA 02116
*Compared to current stenosis-based guidelines 1. Stone, Gregg. PROSPECT II/PROSPECT ABSORB. TCT CONNECT 2020 Late Breaking Trial Session. 2. van Assen, M., et al., Automated plaque analysis for the prognostication of major adverse cardiac events. European Society of Radiology, 2019. 3. Lal B.K., et al. Novel Application of Artificial Intelligence Algorithms to Develop a Predictive Model for Major Adverse Neurologic Events in Patients With Carotid Atherosclerosis. Journal of Vascular Surgery. July 2020. DOI: 10.1016/j.jvs.2020.04.306. Compared to current stenosis based guidelines. 4. Elucid Technology FDA 510k summary – K183012; December 21, 2018.